Bayesian nonparametric strategies for power maximization in rare variants association studies

Lorenzo Masoero EECS, MIT lom@mit.edu Joshua Schraiber Genome Interpretation Group, Illumina Inc jschraiber@illumina.com Tamara Broderick EECS, MIT tamarab@mit.edu

1 Introduction

Next generation sequencing, with larger genomic libraries and higher quality samples, has enabled scientists to start uncovering the genetic basis of disease [Jackson et al., 2018]. Studies of common genomic variants, like genome wide association studies (GWAS), have successfully helped researchers to identify the role of certain *common* variants underlying disease [Visscher et al., 2012, 2017]. While GWAS have had an enormous impact on the understanding of the role of genetic basis in disease, it is now well accepted that common variants — those targeted by GWAS — only partially explain the biology and heritability of disease [Auer and Lettre, 2015]. The large fraction of heritability unexplained by common variants is hypothesized to be largely caused by rare genomic variants [Pritchard, 2001, Zuk et al., 2012]. Hence, rare variants hold great promise: accurate study of their function could largely improve the understanding of the biological underpinning of disease.

The promise and value of studies focusing on rare variants is however hindered by the intrinsic challenges of the task. Rare variants are by their very definition present in few individuals: in order for association studies to reveal many rare variants, they must have large sample sizes, which might be costly. Moreover, extremely rare variants, such as singletons (genetic variants appearing in only one individual within the study) are potentially the most interesting ones from a genetic perspective, but also the hardest to discover. In order to uncover these variants, expensive high quality samples — collected with deep sequencing — are required. Because sequencing studies are always conducted in the presence of limited budgets, devising procedures for optimally allocating this limited budget by tuning the sequencing parameters is an important, although challenging, open problem for practitioners. Indeed, the problem of optimal design in rare variants association studies [RVAS] has a rich history in the genomics literature (Ionita-Laza and Ottman [2011], Momozawa and Mizukami [2020], Cirulli et al. [2020]). Recently, these types of considerations have been of interest also in the single-cell RNA sequencing community [Assefa et al., 2020, Zhang et al., 2020].

Existing literature and our contribution: Within the fast growing literature on rare variants, Rashkin et al. [2017] first considered the problem of optimal design of RVAS for power maximization of an associated statistical burden test. This important contribution provides practitioners with a quantitative framework for trade-offs evaluations when making complex design choices. However, the approach of Rashkin et al. [2017] also suffers from two main limitations: (a) it only applies to burden tests, and (b) does not directly apply to multi-stage optimal experimental design. In the present work, we provide a novel approach for optimal experimental design in RVAS, which tries to overcome the aforementioned limitations (a), (b). We develop a novel, rigorous statistical framework to understand how *design* choices in RVAS can impact their usefulness, and we provide a practical workflow to inform such design choices under a fixed experimental budget. Our approach relies on the formulation of a rigorous statistical Bayesian nonparametric model. In particular, (a) our framework can help practitioners plan a power analysis in the context of any statistical test of interest, including but not limited to burden tests for rare variants, and (b) the Bayesian approach makes our framework automatically amenable to multi-stage optimal experimental design.

Learning Meaningful Representations of Life (NeurIPS 2021), Sydney, Australia.

2 Power trade-offs in RVAS via Bayesian nonparametrics

Rare variants association studies: Association studies test whether alleles are *associated* with disease. This is done by performing a statistical test to assess if the frequency of a set of one or more alleles differs between healthy "control" subjects and affected "cases" in a population of interest. Here we focus on RVAS, association studies designed to test whether *rare* variants are associated with disease. One of the main challenges in RVAS, is that rare variants are hard to find and analyze: when *designing* a RVAS, many factors should be carefully chosen in order to maximize the efficacy of the study — the choice of the type of variants to analyze (e.g., disruptive vs. missense), the threshold for "rare" variants (e.g. observed in less than 1% or 0.1% of the samples), as well as the choice of the study, practitioners must take care when designing the data collection process. In this work, we focus on the downstream impact of sequencing depth and sample sizes in RVAS.

Simple burden tests: As in Zuk et al. [2014], we focus on power analysis for a burden test for a binary trait (presence or absence of disease) in a two-class model, in which alleles are either null (i.e. abolishing function), or neutral (have no effect). We imagine having data from two groups, the affected (A) and unaffected (U) subpopulation, and assume that there exists a given, fixed and known, reference genome (an idealized complete genomic sequence), shared between the two subpopulations. We want to test whether *rare* variants — loci at which only a few individuals show deviation from the reference — are correlated with the presence of disease. We do so by designing a statistical test that counts the abundance of rare variants in samples of affected and unaffected individuals, respectively. Given the reference and a user-specified threshold $\ell \in \{1, 2, \ldots\}$, we let those variants appearing at most ℓ times in the sample be "rare." Take subpopulations A and U with N_A and N_U samples, respectively. We define $\mu_i := \mu_i(N_i, \ell)$ to be the (unknown) average value per individual of rare variants appearing in at most ℓ copies from N_i samples from population $i \in \{A, U\}$. We test

$$H_0: \{\mu_A = \mu_U\}$$
 vs. $H_1: \{\mu_A > \mu_U\}.$ (1)

Test statistic and power: To test H_0 , we need a test statistic T, a function of the data testing H_0 :

$$T = \frac{\bar{\mu}_A - \bar{\mu}_U}{\sqrt{s_A^2/M_A + s_U^2/M_U}},$$
(2)

where M_i is the sample size of population i, $\bar{\mu}_i$ is the average number of ℓ -tons in the sample per person in population i, s_A^2 , s_U^2 are the sample variances of $\bar{\mu}_i$, $i \in \{A, U\}$. T in Equation (2) is the test statistic for a simple burden test; it counts the scaled excess of variants in A relative to U. The *power* of the test at a given confidence $\alpha \in (0, 1)$ is the probability that H_0 is rejected at confidence α given that H_0 is false, $\pi_{\alpha} := \operatorname{pr}(H_0$ rejected at confidence level $\alpha \mid H_0$ false).

Power maximization: optimal trade-off of sequencing depth and breadth under a fixed budget We would like to design studies that help us detect association. Here, we adopt the power π_{α} of the associated burden test as a measure of detection efficacy. We investigate, in the presence of a fixed sequencing capacity (budget), how sequencing depth and power of a simple burden test relate to each other: higher depth comes with the promise of higher quality samples, in which genomic variants are called with higher precision, and in principle higher power. However, a higher sequencing depth also comes at higher cost. For a fixed budget, practitioners need to trade off the sequencing depth with the size of the cohorts sampled. Following Rashkin et al. [2017], we let the cost of sequencing be $c(m,\lambda;\kappa_0,\kappa_1) = m\lambda\kappa_1 + \kappa_0$. Here m denotes the number of samples collected and $\lambda > 0$ is the average sequencing depth. The parameter κ_0 is a library fixed cost, and κ_1 is a per-sample preparation cost. In the simplest case, which we consider in our experiments, $\kappa_0 = 0, \kappa_1 = 1$, and the cost of m samples at depth λ is simply $m\lambda$. κ_0, κ_1 could further depend on the population e.g., to encode the fact that obtaining samples from patients carrying a rare genetic disease might be more expensive than generic controls. Under a fixed budget B > 0, we need to trade off the depth λ and the number M_A, M_U of samples collected. Denoting the power as a function of the sequencing depth, as well as of the sample sizes, $\pi_{\alpha}(M_A, M_U, \lambda)$, we are therefore interested in solving

$$\underset{M_A,M_U,\lambda}{\arg\max} \{\pi_{\alpha}(M_A, M_U, \lambda)\} \text{ subject to } c(M_A + M_U, \lambda; \kappa_0, \kappa_1) \le B.$$
(3)

A Bayesian nonparametric framework for rare variants association tests: To solve Equation (3), we briefly introduce a Bayesian nonparametric [BNP] framework (more details in Appendices B

and D). We assume the underlying *reference* genome to be known. Let N_A, N_U be the number of genomes collected in populations A, U: these are sequences of individuals, which can either agree (no variant) or disagree (variant) with the reference. Let variation be observed at $L < +\infty$ loci among the $N_A + N_U$ genomes collected in population A, U. We let Ω be an arbitrary measurable space of variant labels, and we let $\psi_{\ell} \in \Omega$ be the label of the ℓ -th variant in order of appearance. We let $x_{i,n,\ell}$ equal 1 if the variant with label ψ_{ℓ} is observed for the *n*-th organism in population $i \in \{A, U\}$; otherwise, let $x_{i,n,\ell}$ equal 0. We represent data for the *n*-th organism as a measure that pairs each variant count with the corresponding label: $X_{i,n} := \sum_{\ell=1}^{L} x_{i,n,\ell} \delta_{\psi_{\ell}}$.

We now posit a Bayesian model for the data $X_i = \{X_{i,1}, \ldots, X_{i,N_i}\}, i \in \{A, U\}$. We specify a likelihood function $\operatorname{pr}(X_A, X_U \mid \Theta)$ and endow the latent parameter Θ with a prior $\operatorname{pr}(\Theta)$. Following Masoero et al. [2018, 2021], we adopt the (hierarchical) three-parameter beta-Bernoulli model. We imagine countably many latent variant rate-location pairs, collected in a random measure $\Theta_0 = \sum_{\ell=1}^{+\infty} \theta_{0,\ell} \delta_{\psi_\ell}$. The latent rates $\{\theta_\ell\} \subset [0, 1]$ are modeled as drawn from a three-parameter beta process [Teh and Gorur, 2009, Broderick et al., 2012], parametrized by mass $\alpha > 0$, discount $\sigma \in [0, 1)$, concentration $c > -\sigma$, denoted as $\xi_0 = (\alpha, c, \sigma)$. For subpopulation $i \in \{A, U\}$, every variant ψ_ℓ has a population-dependent parameter $\theta_{i,\ell}$ governing variants occurrence probabilities:

$$\theta_{i,\ell} \mid \Theta_0 \sim \text{Beta} \left\{ a_i \theta_{0,\ell}, b_i (1 - \theta_{0,\ell}) \right\},\tag{4}$$

where $a_i > 0, b_i > 0$ are fixed parameters. For every individual n in every population i, $pr(X_{n,i,\ell} = 1) = \theta_{i,\ell}$: the probability that variant ψ_{ℓ} is present in an individual varies in different populations, but depends on the underlying shared parameter $\theta_{0,\ell}$. Last, because of sequencing error, the actual observed presence or absence of variant ψ_{ℓ} is modeled as $Z_{i,n,\ell} = \mathbf{1}(C_{i,n,\ell,\text{noerror}} \geq D)X_{i,n,\ell}$, where D > 0 is a fixed threshold, and for a fixed $p_{err} \in (0, 1)$ quantifying a technology-dependent sequencing error parameter, $C_{i,n,\ell,\text{noerror}} \sim \text{Poisson}(\lambda(1 - p_{err}))$, i.i.d. across i, n, ℓ .

We leverage the model above to inform the trade-off between sample sizes and depth for power in rare-variants burden tests: the expectation and variance of the number of k-tons (number of variants appearing exactly k times) predicted by our model in population $i \in \{A, U\}$ can be computed through the predictive structure implied by the model. Because this prediction explicitly depends on the sequencing depth, as well as the sample size, our model then captures the trade-off discussed above. Specifically, assuming M_A and M_U samples are collected from the affected and unaffected subpopulation respectively and fixing a common sequencing depth $\lambda > 0$, we can replace the test statistic Equation (2) with a model-based counterpart to inform the power trade offs. Namely:

Q1: Analyze the power of the rare variants burden test as we increase the sample size of the cases and controls, for a fixed sample size, for different choices of the sequencing depth λ .

Q2 Analyze, under a fixed budget, how different sequencing depths and sample sizes affect the power of the burden test, by replacing the test statistic T (Eq. 2) with its model-based counterpart.

3 Experiments

We now move on to the empirical evaluation of the properties of the Bayesian hierarchical model via simulated data from the model. Additional details can be found in Appendices C and E. We address Q1 and Q2 introduced at the end of Section 2. For Q1, in Figure 1 we show how the power of the singleton burden test changes with the sizes of the control and the affected subpopulations, for fixed sequencing depth. Larger sample sizes and higher sequencing depths never harm the power. However, the rate at which power increases depends on the underlying parameters of the model; in real data the same sequencing strategy could prove more or less effective depending on the data. If the experiment under study has the goal of achieving a desired level of power, our framework would allow practitioners to provide estimates of the budget needed in order to achieve the desired power.

For Q2, power maximization under a fixed budget, we consider singletons — variants appearing at most once (see Appendix E for k-tons, $k \in \{2, 3, 4, 5\}$). In line with Rashkin et al. [2017, Figures 4,5], we find that the optimal sequencing depth is relatively insensitive to the available budget (Figure 2). Moreover, we find that tests for extremely rare variants generally achieve higher power than tests for relatively less rare variants (Figure 12). The intuition has to be sought in the properties of the model's frequency distribution: the underlying three-parameter beta process prior used here suggests that most variants are extremely rare. Therefore, when testing for extremely rare variants, the test has sufficient power even when the sequencing depth is relatively low, just



Figure 1: Top row: number of singletons in the affected (solid) and unaffected (dashed) subpopulations (vertical axis), for various sequencing depths (green: $\lambda = 22$, orange: $\lambda = 25$, blue: $\lambda = 40$, horizontal axis). Bottom row: power of the test (vertical axis) for a given sample size (horizontal axis). Different columns refer to different parameters of Θ_0 — left: $\boldsymbol{\xi}_0 = [5, 4, 0.5]$, center: $\boldsymbol{\xi}_0 = [8, 5, 0.55]$, right: $\boldsymbol{\xi}_0 = [10, 6, 0.6]$. For all subplots, $a_1 = 200, a_2 = 150, b_1, b_2 = 100$.



Figure 2: Power of the singletons hypothesis burden test for H_0 (vertical axis) as the sequencing depth changes (horizontal axis) under a fixed sequencing capacity (i.e. budget) constraint (Q2). Different lines report results for different budgets. Different columns refer to different choices of the hyperparameters of the underlying shared measure Θ_0 — left $\boldsymbol{\xi}_0 = [5, 4, 0.5]$, center $\boldsymbol{\xi}_0 = [8, 5, 0.55]$, right $\boldsymbol{\xi}_0 = [10, 6, 0.6]$. For all subplots, $a_A = 200, a_U = 150, b_A = 100, b_U = 100$.

because on average the affected population will reveal a larger number of singletons with respect to the unaffected population. When testing for relatively more-frequent variants, a larger depth is needed in order to capture a significant discrepancy between the affected and unaffected population.

4 Discussion

We introduced a novel BNP approach for optimal design for power maximization in RVAS. We showed with simulations that our model can be a useful tool to inform complex experimental design choices, especially under a fixed budget constraint. We envision several extensions to our work:

Posterior analyses: Our method could be used for multi-stage sequencing design, i.e. when scientists have existing data, and have to optimally design future experiments [Pahl et al., 2009].

Beyond simple burden tests: Because of the statistical framework for the data generating process, our method can be used for other tests (e.g., Sequence Kernel Association Test [Wu et al., 2011]).

Variant calling rules: We here followed Ionita-Laza and Laird [2010] and used a simple threshold rule for variant calling. Evaluating sensitivity variant callers, and producing results for genotype variant calling rules [Nielsen et al., 2011] could further enhance the usefulness of our approach.

Acknowledgments Lorenzo Masoero and Tamara Broderick were supported in part by the DARPA I2O LwLL program, an NSF CAREER Award, and ONR.

References

- A. T. Assefa, J. Vandesompele, and O. Thas. On the utility of rna sample pooling to optimize cost and statistical power in rna sequencing experiments. *BMC genomics*, 21(1):1–14, 2020.
- P. L. Auer and G. Lettre. Rare variant association studies: considerations, challenges and opportunities. *Genome medicine*, 7(1):1–11, 2015.
- T. Broderick, M. I. Jordan, and J. Pitman. Beta processes, stick-breaking and power laws. *Bayesian Analysis*, 7(2):439–476, 2012.
- T. Broderick, A. C. Wilson, and M. I. Jordan. Posteriors, conjugacy, and exponential families for completely random measures. *Bernoulli*, 24(4B):3181–3221, 2018.
- S. Chakraborty, A. Arora, C. B. Begg, and R. Shen. Using somatic variant richness to mine signals from rare variants in the cancer genome. *Nature communications*, 10(1):1–9, 2019.
- E. T. Cirulli, S. White, R. W. Read, G. Elhanan, W. J. Metcalf, F. Tanudjaja, D. M. Fath, E. Sandoval, M. Isaksson, and K. A. Schlauch. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. *Nature communications*, 11(1):1–10, 2020.
- S. Gravel. Predicting discovery rates of genomic features. Genetics, 197(2):601-610, 2014.
- T. L. Griffiths and Z. Ghahramani. The Indian buffet process: An introduction and review. *Journal of Machine Learning Research*, 12(4), 2011.
- D. A. Harrison and A. R. Brady. Sample size and power calculations using the noncentral tdistribution. *The Stata Journal*, 4(2):142–153, 2004.
- I. Ionita-Laza and N. M. Laird. On the optimal design of genetic variant discovery studies. *Statistical Applications in Genetics and Molecular Biology*, 9(1), 2010.
- I. Ionita-Laza and R. Ottman. Study designs for identification of rare disease variants in complex diseases: the utility of family-based designs. *Genetics*, 189(3):1061–1068, 2011.
- I. Ionita-Laza, C. Lange, and N. M. Laird. Estimating the number of unseen variants in the human genome. *Proceedings of the National Academy of Sciences*, 106(13):5008–5013, 2009.
- M. Jackson, L. Marks, G. H. May, and J. B. Wilson. The genetic basis of disease. *Essays in biochemistry*, 62(5):643–723, 2018.
- L. F. James. Bayesian Poisson calculus for latent feature modeling via generalized Indian buffet process priors. *The Annals of Statistics*, 45(5):2016–2045, 2017.
- L. Masoero, F. Camerlenghi, S. Favaro, and T. Broderick. Posterior representations of hierarchical completely random measures in trait allocation models. *BNP@NeurIPS*, 2018.
- L. Masoero, F. Camerlenghi, S. Favaro, and T. Broderick. More for less: predicting and maximizing genomic variant discovery via Bayesian nonparametrics. *Biometrika*, 02 2021.
- O. Mayo. A century of Hardy–Weinberg equilibrium. *Twin Research and Human Genetics*, 11(3): 249–256, 2008.
- Y. Momozawa and K. Mizukami. Unique roles of rare variants in the genetics of complex diseases in humans. *Journal of Human Genetics*, pages 1–13, 2020.
- R. Nielsen, J. S. Paul, A. Albrechtsen, and Y. S. Song. Genotype and snp calling from nextgeneration sequencing data. *Nature Reviews Genetics*, 12(6):443–451, 2011.
- R. Pahl, H. Schäfer, and H.-H. Müller. Optimal multistage designs—a general framework for efficient genome-wide association studies. *Biostatistics*, 10(2):297–309, 2009.
- J. K. Pritchard. Are rare variants responsible for susceptibility to complex diseases? *The American Journal of Human Genetics*, 69(1):124–137, 2001.

- S. Rashkin, G. Jun, S. Chen, G. R. Abecasis, Genetics, and E. of Colorectal Cancer Consortium. Optimal sequencing strategies for identifying disease-associated singletons. *PLoS genetics*, 13 (6):e1006811, 2017.
- J. A. Reuter, D. V. Spacek, and M. P. Snyder. High-throughput sequencing technologies. *Molecular cell*, 58(4):586–597, 2015.
- Y. W. Teh and D. Gorur. Indian buffet processes with power-law behavior. In Advances in Neural Information Processing Systems, pages 1838–1846, 2009.
- R. Thibaux and M. I. Jordan. Hierarchical beta processes and the indian buffet process. In Artificial Intelligence and Statistics, pages 564–571. PMLR, 2007.
- P. M. Visscher, M. A. Brown, M. I. McCarthy, and J. Yang. Five years of gwas discovery. *The American Journal of Human Genetics*, 90(1):7–24, 2012.
- P. M. Visscher, N. R. Wray, Q. Zhang, P. Sklar, M. I. McCarthy, M. A. Brown, and J. Yang. 10 years of gwas discovery: biology, function, and translation. *The American Journal of Human Genetics*, 101(1):5–22, 2017.
- B. L. Welch. The generalization of 'student's' problem when several different population variances are involved. *Biometrika*, 34(1-2):28–35, 1947.
- J. E. Wigginton, D. J. Cutler, and G. R. Abecasis. A note on exact tests of Hardy-Weinberg equilibrium. *The American Journal of Human Genetics*, 76(5):887–893, 2005.
- M. C. Wu, S. Lee, T. Cai, Y. Li, M. Boehnke, and X. Lin. Rare-variant association testing for sequencing data with the sequence kernel association test. *The American Journal of Human Genetics*, 89(1):82–93, 2011.
- C. Xu. A review of somatic single nucleotide variant calling algorithms for next-generation sequencing data. *Computational and Structural Biotechnology Journal*, 16:15–24, 2018.
- M. J. Zhang, V. Ntranos, and D. Tse. Determining sequencing depth in a single-cell rna-seq experiment. *Nature communications*, 11(1):1–11, 2020.
- J. Zou, G. Valiant, P. Valiant, K. Karczewski, S. O. Chan, K. Samocha, M. Lek, S. Sunyaev, M. Daly, and D. G. MacArthur. Quantifying unobserved protein-coding variants in human populations provides a roadmap for large-scale sequencing projects. *Nature communications*, 7(1):1–5, 2016.
- O. Zuk, E. Hechter, S. R. Sunyaev, and E. S. Lander. The mystery of missing heritability: Genetic interactions create phantom heritability. *Proceedings of the National Academy of Sciences*, 109 (4):1193–1198, 2012.
- O. Zuk, S. F. Schaffner, K. Samocha, R. Do, E. Hechter, S. Kathiresan, M. J. Daly, B. M. Neale, S. R. Sunyaev, and E. S. Lander. Searching for missing heritability: designing rare variant association studies. *Proceedings of the National Academy of Sciences*, 111(4):E455–E464, 2014.

A Simple burden tests: additional details

In this work, following Zuk et al. [2014], we focus on the simplest possible power analysis for rare variants association studies: we consider burden tests for a binary trait (presence or absence of disease) in a two-class model, in which all alleles are either null (i.e. abolishing gene function), or neutral (have no effect on gene function). That is, we imagine having data from two groups, an affected (A) and unaffected (U) subpopulation, and design a (statistical) burden test with the goal of understanding if certain rare genomic variants are correlated with the presence of disease by counting their abundance in samples of affected and unaffected individuals respectively. In particular, we imagine that there exists a given, fixed and known, reference genome, shared between the two subpopulations. And we interested in testing for *rare* variants. Here, given the reference and a userspecified threshold $\ell \in \{1, 2, \ldots\}$, we let "rare" variants be those variants appearing at most ℓ times, with $\ell \ge 1$ in the sample. Take subpopulations *i* and *j*, with $i \ne j$. Assume subpopulations *i* and *j* have N_i and N_j samples, respectively. Then we define

- *μ_i* := *μ_i*(*N_i*, *ℓ*) to be the (unknown) average value per individual of rare variants appearing
 in at most *ℓ* copies from *N_i* samples from population *i*
- $\mu_i^* := \mu_i^*(N_i, N_j, \ell)$ to be the (unknown) mean value per individual of rare variants appearing at most in ℓ copies from N_i samples from population *i*, and *not* appearing in any of N_i samples from population *j*

Variants are computed with respect to a known reference genome, shared by the two subpopulations. We then want to test the hypotheses

$$H_0: \{\mu_A = \mu_U\}$$
 vs. $H_1: \{\mu_A > \mu_U\},\$

and

$$H_0^{\star}: \{\mu_A^{\star} = \mu_U^{\star}\}$$
 vs. $H_1^{\star}: \{\mu_A^{\star} > \mu_U^{\star}\}.$ (5)

A special instance of this hypothesis test — considered in Rashkin et al. [2017] — is the one in which $\ell = 1$, i.e., those variants that have only been observed once in the sample. We henceforth investigate, in the presence of a fixed *sequencing capacity*, how sequencing depth and power of a simple burden test relate to each other. And specifically,

- Given a fixed experimental design, and potentially an existing study, how will the power of the burden test change as we increase the sample sizes of the affected and unaffected samples?
- Given a fixed budget, and potentially an existing study, how should practitioners design a follow-up study to maximize the power of a simple burden test, trading off depth of the sequencing and size of the affected and unaffected cohorts?

A.1 Test statistic, null distribution, power

We now introduce a statistical framework for power analysis in the simple burden test introduced in Equation (1), building on the approach of Rashkin et al. [2017].

We test the null hypothesis H_0 in Equation (1). The same assumptions made for the null hypothesis Equation (1) are also made for the hypothesis test in Equation (5) — we here omit the statements.

First, for testing H_0 , we compute the test statistic already defined in Equation (2):

$$T = \frac{\bar{\mu}_A - \bar{\mu}_U}{\sqrt{s_A^2/M_A + s_U^2/M_U}},$$
(6)

where

- M_A, M_U are the sample sizes of group A, U respectively
- $\bar{\mu}_A, \bar{\mu}_U$ are the average number in the sample of ℓ -tons per person in A, U respectively
- s_A^2, s_U^2 are the sample variances of $\bar{\mu}_A, \bar{\mu}_U$ respectively

Assumption 1 (Distribution under the null). Under H_0 , we assume that $\bar{\mu}_A$, $\bar{\mu}_U$ are normally distributed with the same mean, but potentially unequal variances. Then, the test statistic T in Equation (2) follows a (centered) Student's-t distribution with (approximate) degrees of freedom given by the Welch-Satterwaite equation [Welch, 1947],

$$\phi_0 = \frac{\left(\frac{s_A^2}{M_A} + \frac{s_U^2}{M_U}\right)^2}{\frac{s_A^2}{M_A^2(M_A - 1)} + \frac{s_U^4}{M_U^2(M_U - 1)}}$$

i.e.

$$T \mid H_0 \sim \tau(\phi_0, 0).$$

Hence, for a given confidence level $\alpha \in [0, 1]$, we reject the null hypothesis H_0 if the test statistic is sufficiently large, namely $T > t_{1-\alpha}(\phi_0, 0)$ — where $t_{1-\alpha}(\phi_0, 0)$ is the $(1 - \alpha) \times 100\%$ percentile of a (centered) t-distribution with ϕ_0 degrees of freedom, i.e. $\operatorname{pr}(T > t_{1-\alpha}(\phi_0, 0) \mid H_0) = \alpha$.

Assumption 2 (Power of two-sample *t*-test). The power of the test,

$$\pi_{\alpha}(M_A, M_U) := \operatorname{pr}(H_0 \text{ rejected at confidence level } \alpha \mid H_0 \text{ false})$$
(7)

is computed as

 τ

$$\pi_{\alpha}(M_A, M_U) = \Pr\left[X > t_{1-\alpha}(\phi_0, 0) \mid X \sim \tau(\phi_0, T)\right],\tag{8}$$

where $t_{\alpha/2}(\phi_0, 0)$ is the $(1 - \alpha/2) \times 100\%$ percentile of the (central) t-distribution with ϕ_0 degrees of freedom, while $\tau(\phi_0, \lambda)$ is the law of a random variable following a non-central Student's-t distribution with ϕ_0 degrees of freedom and noncentrality parameter λ [Harrison and Brady, 2004].

B A Bayesian nonparametric framework for power maximization

In this section, we provide additional details and background on the Bayesian nonparametric approach used in Section 2 to address the trade-off discussed in Section 2. In this section, we consider a simple nonparametric model, in which (i) the arising of variants in different subpopulations is modeled independently, and (ii) we treat genomes as haploid sequences. While simplistic, this model allows us to build intuition. Next, in Appendix D, we introduce a hierarchical generalization of our model, so as to be able to model the arising of diploid variants in multiple subpopulations jointly.

Our present model, and its justification, coincide with Masoero et al. [2021] — there in the context of genomic variants prediction. We here briefly describe it, by considering the case of a single subpopulation in the simpler case in which the data is collected without any sequencing error.

B.1 Observational model without sequencing errors

With the advent of next-generation sequencing, it is now possible to determine with high precision an organism's genome [Reuter et al., 2015]. When studying a population of interest, a first step towards the understanding of the landscape of variation within the population is the definition of a *reference* genome: a fixed representative sequence for the whole population. While several forms of variants exist (missense, truncation, translocation, etc.), in the present work we treat all types of variation from the reference as equal.

Let N be the number of genomes collected: these are (genomic) sequences of individuals, which can either agree (no variant) or disagree (variant) with an underlying fixed reference genome at a large, finite number of loci. Let L be the number of loci at which variation is observed among the first N genomes collected, $0 \le L < +\infty$. We let Ω be an arbitrary measurable space of variants labels, and $\psi_{\ell} \in \Omega$ be the label of the ℓ -th variant in order of appearance, and $x_{n,\ell}$ equal 1 if the variant with label ψ_{ℓ} is observed for the n-th organism; otherwise, let $x_{n,\ell}$ equal 0. We collect data for the n-th organism in a measure which pairs each variant observation with the corresponding variant label: $X_n := \sum_{\ell=1}^{L} x_{n,\ell} \delta_{\psi_{\ell}}$.

Given the data X_1, \ldots, X_N , we now posit a Bayesian model for it. This requires us to specify a generative model for the data, via a likelihood function $pr(X_1, \ldots, X_N | \Theta)$, and endow the latent parameter Θ with an adequate prior distribution $pr(\Theta)$. Following Masoero et al. [2021], we here adopt the three-parameter beta-Bernoulli model. In this model, we imagine an underlying countable infinity of latent variants rate-location pairs, labelled as $\{(\theta_\ell, \psi_\ell)\}_{\ell \ge 1}$, which are the realization of a Poisson point process, whose distribution is characterized by the following rate measure on $[0, 1] \times \Omega$:

$$\nu(\mathrm{d}\theta)P_0(\mathrm{d}\omega) = \alpha \frac{\Gamma(1+c)}{\Gamma(1-\sigma)\Gamma(c+\sigma)} \theta^{-1-\sigma} (1-\theta)^{c+\sigma-1} \mathbf{1}_{[0,1]}(\theta) \mathrm{d}\theta P_0(\mathrm{d}\omega),\tag{9}$$

where $\mathbf{1}_A(\theta)$ is equal to 1 if the argument θ belongs to the set A, and 0 otherwise. Here P_0 is an arbitrary diffuse measure on the space Ω , and will be irrelevant in our discussion. We henceforth ignore it, and write $\Theta \sim 3BP(\alpha, \sigma, c)$ to denote a Poisson point process with Lévy mean measure as above. If we impose $\alpha > 0, \sigma \in [0, 1), c > -\sigma$, then Θ can be seen as a discrete random measure on Ω , with countably many atoms, and such that the sum of the rates is finite. That is, we can represent Θ as follows:

$$\Theta = \sum_{\ell \ge 1} \theta_\ell \delta_{\psi_\ell}.$$

By construction, the rates $\{\theta_\ell\}_{\ell\geq 1}$ are all values in [0,1]: we interpret then each rate θ_ℓ as the probability that the corresponding variant ψ_ℓ is present in an individual, independently of any other individual and variant. I.e., conditionally on Θ , we let X_n be a Bernoulli process with underlying rate measure $\Theta - X_n \sim \text{BeP}(\Theta)$. We write $X_n := \sum_{\ell\geq 1} x_{n,\ell} \delta_{\psi_\ell}$; since $x_{n,\ell} = 0$ for all unobserved variants, this equation reduces to the previous definition of X_n above. Then, the model allows the observed number of variants to be finite for any finite dataset, and grow without bound as the number of observations increases [Teh and Gorur, 2009, James, 2017, Broderick et al., 2018]. To sum up:

$$\Theta \sim 3BP(\alpha, c, \sigma), \quad X_n \mid \Theta \sim BeP(\Theta), \quad n = 1, \dots, N.$$
 (10)

B.2 Observations in the presence of sequencing errors

The model given in Appendix B.1 describes a data generating process that does not take into account the presence of sampling error in the sequencing procedure. I.e., it implicitly assumes that variants are detected without error whenever present. However, in practice, sequencing is a complex and noisy process, in which millions of reads of fragments of the same genomic sequence need to be aligned and compared to the reference genome. In this process, several mistakes can be made when reconstructing the genomic sequence.

Now, following again Masoero et al. [2021], we introduce a modification of our model that takes into account the error induced by sequencing. Let X_n be the underlying, true value of the binary genotype sequence associated with individual n. We assume that, in the presence of sequencing errors, observations are obtained by down-weighting the probability of actually observing a variant:

1. For each individual n, each locus in the sequence is read a random number of times $C_{n,\ell}$. Given a sequencing depth $\lambda > 0$, we assume

$$C_{n,\ell} \stackrel{\text{iid}}{\sim} \text{Poisson}(\lambda).$$

2. Each of these reads is either correctly processed, or incurs some form of reading error. We assume that

$$C_{n,\ell,\text{noerror}} \sim \text{Binomial}(C_{n,\ell}, 1 - p_{err}).$$

Here $p_{err} \in [0, 1)$ is a technology-dependent, known parameter.

3. We let D be a threshold parameter for a simple variant calling rule — fixed a priori. Then, a variant at locus ℓ for individual n is called according to the following variant-calling rule:

$$Z_{n,\ell}(\lambda, D, p_{err}) = \mathbf{1}(C_{n,\ell,\text{noerror}} \ge D)X_{n,\ell}.$$
(11)

Remark 1. *Given steps 1.—3. above, the probability of obtaining at least D correct reads from the Poisson-binomial sampling described is given by*

$$\begin{split} \phi &:= \phi(\lambda, D, p_{err}) = \sum_{d \ge D} \frac{e^{-\lambda} \lambda^d}{d!} \sum_{i=D}^d \binom{d}{i} (1 - p_{err})^i p_{err}^{d-i} \\ &= \sum_{d \ge D} \frac{e^{-\lambda(1 - p_{err})} \{\lambda(1 - p_{err})\}^d}{d!}. \end{split}$$

Then, it follows that for all $n, \ell, Z_{n,\ell} \mid \theta \sim \text{Bernoulli}(\phi \theta_{\ell})$. I.e.,

$$Z_n(\lambda, D, p_{err}) \mid \theta \sim \operatorname{BeP}(\phi\theta).$$
(12)

As discussed in Masoero et al. [2021], the simple threshold variant calling rule used here is a simplification of modern variant callers employed in genomic pipelines (see Xu [2018] for a review of variant calling algorithms). Exploring how to embed alternative variant calling rules within the present formulation is an exciting direction for future work, as discussed in Section 4.

B.3 Distributional results from the model

After introducing a model for sequencing in the presence of noise in Appendix B.2, we now complete our derivation so as to be able to use the model for the problem of optimal experimental design of burden tests under a fixed budget, previously discussed in Section 1. Specifically, we characterize the predictive behavior for the number of rare variants induced by the model. This quantity can be used in order to solve the power maximization problem discussed in Equation (3). In particular, we first predict how many new rare variants are going to be discovered in future samples, as a function of the sequencing depth and the extrapolation size. As a direct consequence, we can use these predictions to analyze how the power of the corresponding burden test is going to be affected, and in turn aid experimental design. We now state the key distributional results implied by the model. See Masoero et al. [2021, Proposition A.3] for a proof of this proposition.

Proposition 2. Let Z_1, \ldots, Z_N be $N \ge 0$ training draws from the Bayesian nonparametric model Equation (12), collected at sequencing depth $\lambda_{pilot} > 0$, for a fixed variant calling threshold $D \in \mathbb{N}$ and sequencing error $p_{err} \in [0, 1]$,

$$Z_n \mid \theta, \lambda_{pilot}, D, p_{err} \stackrel{\text{nd}}{\sim} \text{BeP}(\phi\theta), n = 1, \dots, N \text{ and } \theta \sim 3\text{BP}(\alpha, c, \sigma)$$

For a given frequency $k \in \{1, ..., M\}$, the number $U_N^{(M,k)}$ of variants appearing exactly k times in M additional samples now at adjusted sequencing depth $\lambda_{follow} > 0$, conditionally on the first N observations $Z_{1:N}$ is given by

$$U_N^{(M,k)} \mid Z_{1:N}, \lambda_{pilot}, \lambda_{follow}, D, p_{err} \sim \text{Poisson}(\gamma_k),$$

where, letting $\phi_{pilot} = \phi(\lambda_{pilot}, D, p_{err})$ and $\phi_{follow} = \phi(\lambda_{follow}, D, p_{err})$

$$\gamma_k := \gamma_k(N, M, \phi_{pilot}, \phi_{follow}, \boldsymbol{\xi})$$

$$= \alpha \binom{M}{k} (\phi_{follow})^k \frac{(1+c)_{k-1\uparrow}}{(1-\sigma)_{k-1\uparrow}} \mathbb{E}\left[(1-\phi_{follow}B)^{M-k} (1-\phi_{pilot}B)^N \right].$$

$$(13)$$

Here, $B \sim \text{Beta}(k - \sigma, c + \sigma)$, and $(a)_{b\uparrow} := \Gamma(a + b)/\Gamma(a)$. Under our model, observations are exchangeable — equivalently, conditionally i.i.d. given the underlying random parameter θ . Then, conditionally on past samples Z_1, \ldots, Z_N , the number of new variants per sample which appear exactly k times in the M new samples must be distributed as

$$S_N^{(M,k)} \mid Z_{1:N} \sim \text{Poisson}\left(\frac{\gamma_k}{M}\right).$$
 (14)

B.4 Power analysis: prior analyses and follow-up designs

We have now all the ingredients to illustrate how the Bayesian formulation proposed above can aid optimal experimental design, when the goal is to maximize the power of a burden test for rare variants like the one presented in Equation (2). In what follows, we will focus on the burden test introduced in Section 2.

We consider again the case of two subpopulations — the affected ("A") and unaffected ("U") respectively. Given hyperparameters $\boldsymbol{\xi}_j = [\alpha^{(j)}, c^{(j)}, \sigma^{(j)}]$ for $j \in \{A, U\}$, we leverage the predictive behavior given in Equation (14) to inform the trade-off between sample sizes and depth for power in rare-variants burden tests. In particular, the expected number of k-tons (number of variants appearing exactly k times) predicted by our model in population $j \in \{A, U\}$, is directly computed from Proposition 2 for the special case N = 0. And since this prediction explicitly depends on the sequencing depth, as well as the (total) sample size, our model then captures the trade-off discussed in Section 1. Given hyperparameters $\boldsymbol{\xi}_j$, let $\gamma_k^{(j)} := \gamma_k(0, M, 1, \phi_j, \boldsymbol{\xi}_j)$ be the expected number of k-tons in M samples in population j (see Equation (13)). Then, assuming M_A and M_U samples are collected from the affected and unaffected subpopulation respectively, and fixing a common sequencing depth $\lambda > 0$, we compute

$$T(M_A, M_U, \lambda \mid \boldsymbol{\xi}_A, \boldsymbol{\xi}_U) = \frac{\frac{\gamma_{k_A}^{(A)} - \frac{\gamma_{k_U}^{(U)}}{M_U}}{\sqrt{\frac{\gamma_{k_A}^{(A)} + \frac{\gamma_{k_U}^{(U)}}{M_A^2} + \frac{\gamma_{k_U}^{(U)}}{M_U^2}}}.$$
(15)

T above is a model-based counterpart of the burden test statistic given in Equation (2). Then, under the assumptions in Appendix A, and using the additional approximation that for μ large, the distribution of $X \sim \text{Poisson}(\mu)$ is well approximated by a Gaussian distribution with mean and variance μ , we can use Equation (15) to provide a model-based answer to both questions Q1 and Q2 in Section 1. Namely, we can:

- Q1: Analyze how the power of the rare variants burden test changes as we increase the sample size of the cases and controls, for a fixed sample size. Under our model, this analysis will depend on (i) the underlying hyperparameters ξ_j governing the rare variants distributions, and (ii) the choice of the sequencing depth λ .
- Q2: Analyze, under a fixed budget, how different choices of *feasible* sequencing depths and sample sizes will affect the power of the burden test. In particular, we do so by leveraging Assumption 2, where we now replace the test statistic T in Equation (8) with its model-based counterpart defined in Equation (15).

While in the present manuscript we focus on prior analyses, we emphasize that the model could also be helpful for the design of a follow-up study, when the goal is to maximize the usefulness of budget allocation in a multi-stage experiment. That is, given pilot data from both the affected and unaffected subpopulations, we could first infer the underlying parameters ξ_A , ξ_U from the data (e.g., via an empirical Bayes procedure), and then, using these inferred values, design a follow-up study with the goal of maximizing the power of a burden test that is using future samples.

C Experiments

We now present experimental results using the model described in Appendix B. In our experiments, we perform *prior* analyses, and report results similar to the ones obtained by Rashkin et al. [2017]. Specifically, we first perform a thorough investigation of how different configurations of the model's hyperparameters affect the data generating process in Appendix C.1. Then, we move on to the power analysis trade-offs in Appendix C.2. Throughout our experiments, we fix the threshold for the variant calling rule to D = 30, and the error probability to $p_{err} = 0.05$.

C.1 New, rare and excess variants in the Bayesian nonparametric model

We here provide a thorough analysis of synthetic data generation from the Bayesian nonparametric model introduced in Appendix B. In particular, we investigate (i) the role of the hyperparameters α, c, σ as well as (ii) the effect of sequencing depth on the rate at which rare variants appear in draws from the model.

First, we show in Figure 3 simple draws from the three-parameter beta Bernoulli model, for different configurations of the model's hyperparameters and sequencing depth. In order to draw Bernoulli processes X_n , n = 1, 2, ..., we here resort to the exact "marginal scheme" (the Indian buffet process [IBP] [Thibaux and Jordan, 2007, Teh and Gorur, 2009]). A draw from the model is a sparse binary matrix, with a random number of columns (variants). The rate at which the number of columns grows as we increase the number of rows (samples) is governed by the hyperparameters of the process (see, e.g., Masoero et al. [2021, Proposition 2]). When we also consider the effect of sequencing errors, lower sequencing depths prevent us from uncovering all the underlying genetic variation due to sampling noise. In particular, we might miss a large fraction of *rare* variants.

Next, we move on to considering two distinct populations, "affected" A and "unaffected" U, each population with its own set of parameters. For these experiments, we fix $\boldsymbol{\xi}_A = [10, 0.5, 0.1]$ and $\boldsymbol{\xi}_U = [8, 0.3, 1]$. While these choices are arbitrary, they are such that the null hypothesis H_0 is enforced. Namely, draws from the first set of parameters $\boldsymbol{\xi}_A$ give rise (in expectation) to a larger number of rare variants than the corresponding draws given $\boldsymbol{\xi}_U$, as depicted in Figure 4.

An important feature of our model, is that it allows us to control the rate of additional variants we expect to see in the affected population with respect to the unaffected population. Conditionally on fixed $N \geq 0$, observations from the model, we denote by $U_N^{(M)}(\boldsymbol{\xi}_j)$ the number of new variants to be observed in M new samples given N samples in population $j \in \{A, U\}$ — where we emphasize the dependence of this quantity on the hyperparameter $\boldsymbol{\xi}_j$. Similarly, we let $U_N^{(M,r)}(\boldsymbol{\xi}_j)$ denote the



Figure 3: Predictive behavior of the 3BP-Bernoulli model (Equation (10)) under different choices of the hyperparameters. Each row refers to different choices of the model's hyperparameters. For each row, the subplot in the left column shows the binary matrix $X = [X_{n,\ell}]$ of Bernoulli processes, in which $X_{n,\ell} = 1$ (black square) if the *n*-th observation shows variation at locus ℓ . The subplot in the central column shows instead the number of distinct variants present in the underlying binary matrix (vertical axis) as a function of the sample size (horizontal axis). Different colors and different line styles are used to denote different frequencies (blue: all variants, orange: r = 1, green: r = 2, red: $r \leq 5$) at which variants occur. Last, the subplot in the right column reports the total number of observed distinct variants, under sequencing error, as the sequencing depth λ varies. The underlying hyperparameters are $\boldsymbol{\xi} = [5, 5, 0.1]$ (first row), $\boldsymbol{\xi} = [8, 7, 0.2]$ (second row) and $\boldsymbol{\xi} = [10, 15, 0.3]$ (third row).



Figure 4: Predictive behavior of the 3BP-Bernoulli model (Equation (10)) in the absence of sequencing error. Here, $\boldsymbol{\xi}_A = [10, 0.5, 0.1]$ and $\boldsymbol{\xi}_U = [8, 0.3, 1]$. In the left subplot, we show for both configuration of parameters the expected behavior of the number of distinct variants (vertical axis), K_N , as N increases (horizontal axis). In the central subplot, we show the expected number of singletons (vertical axis) as N increases (horizontal axis). Last, in the right subplot, we show the expected number of singletons *per individual* (vertical axis) as N increases (horizontal axis). Shaded bands report 95% credible intervals.



Figure 5: Excess variants ratios for the 3BP-Bernoulli model (Equation (10)). Here, like in Figure 4, $\boldsymbol{\xi}_A = [10, 0.5, 0.1]$ and $\boldsymbol{\xi}_U = [8, 0.3, 1]$. In the left subplot, we show how the excess variants ratio $\epsilon_0^{(N,r)}$ (vertical axis) changes as a function of the sample size N (horizontal axis). Different lines show results for different frequencies. In the right subplot, for a fixed sample size N, we show on the vertical axis the excess variants ratio between the affected and unaffected population as we vary the variants' frequency (horizontal axis). Different lines correspond to different sample sizes $N \in \{10^2, 10^3, 10^4\}$. In both subplots, we place a horizontal line at 1. This corresponds to the case in which both subpopulations show the same number of variants.

number of new rare variants, observed exactly r times in M new samples given the N original ones. Then, we define the "excess variants ratio" for the total and rare number of variants respectively to be

$$\epsilon_N^{(M)} := rac{U_N^{(M)}(\boldsymbol{\xi}_A)}{U_N^{(M)}(\boldsymbol{\xi}_U)}, \quad ext{and} \quad \epsilon_N^{(M,r)} := rac{U_N^{(M,r)}(\boldsymbol{\xi}_A)}{U_N^{(M,r)}(\boldsymbol{\xi}_U)}$$

Here $\epsilon_N^{(M)}$ is the total excess ratio, while $\epsilon_N^{(M,r)}$ is the excess ratio of variants appearing with frequency r. We show in Figure 5 how different parameter specifications lead to different excess variants ratios (see Figure 5).

We conclude our preliminary exploration by analyzing how each hyperparameter in the model affects the excess variants ratio (see Figure 6). We do so by comparing the value of $\epsilon_N^{(M)}$, $\epsilon_N^{(M,r)}$ as we vary in turn each of the three hyperparameters of ξ_A , while keeping the other two parameters fixed, and equal to the value of the parameters in $\xi_U = [10, 10, 0.5]$. First, the "mass" parameter $\alpha > 0$ simply scales the total variants' distribution, uniformly across the spectrum. We show in the left subplot of Figure 6 how increasing α has the effect of linearly increasing the excess variant ratio $\epsilon_N^{(M,r)}$, in the same way for all $r \ge 1$. The effect of the concentration parameter c, and of the discount parameter σ , are more subtle. In general, larger values of c, σ are large, the majority of variants are rare, observed in few individuals, while common variants are less present.

Overall, the preliminary analyses presented here display how the Bayesian nonparametric model introduced in Appendix B is a flexible model, able to capture a wide range of data generating regimes.

C.2 Power analysis with the Bayesian nonparametric model

We now move to the power analysis for the rare variants burden test introduced in Appendix A. We focus on prior analyses for the "balanced samples" case. I.e. we always consider $N_A = N_U = 0$ (no prior samples), and $M_A = M_U$. Further, we assume that the cost is linear in the samples and the depth — that is, there is no library preparation cost, and the cost of sequencing m samples at depth λ is given by $c(m, \lambda) = m\lambda$ (i.e., $\kappa_0 = 0$, $\kappa_1 = 1$ in the RHS of Equation (3)).

Fixed design. We start by considering the "fixed design" case (Q1). We here focus on singletons, i.e. the case r = 1. We are interested in understanding how the statistical power of the burden test changes as a function of the number of samples collected, for a fixed sequencing depth. That is, we imagine that the sequencing depth of the experiment is fixed, and experimenters are interested in



Figure 6: Hyperparameters' role in controlling excess variants ratios for the 3BP-Bernoulli model (Equation (10)). Here, we consider fixed N = 0, M = 100. In all three subplots, we fix the hyperparameters of the unaffected subpopulation to be $\boldsymbol{\xi}_U = [10, 10, 0.5]$. In turn, in each subplot, we let two of the three hyperparameters governing the affected subpopulation coincide with $\boldsymbol{\xi}_U$, and consider how the excess ratio of rare variants varies as we vary the third hyperparameter (left: $\alpha \in [1, 20]$, center: $c \in [1, 20]$, right: $\sigma \in [0, 1)$). We report on the vertical axis the excess variants ratio $\epsilon_0^{100,r}$, for different choices of $r \in \{1, 2, 5, 10\}$, as we vary the value of a single hyperparameter.



Figure 7: Power analysis under fixed design. In each column, we consider two different subpopulations (affected, and unaffected individuals). The data generating process of each group is driven by different sets of hyperparameters (left: $\boldsymbol{\xi}_A = [10, 4, 0.2], \boldsymbol{\xi}_U = [7, 3, 0.1]$, center: $\boldsymbol{\xi}_A = [15, 8, 0.5],$ $\boldsymbol{\xi}_U = [14, 6, 0.4]$, right: $\boldsymbol{\xi}_A = [24, 12, 0.5], \boldsymbol{\xi}_U = [20, 10, 0.3]$). In each subplot, we show under fixed sequencing budget how different sequencing depth choices (different colored lines) affect the power of the singletons burden test as we increase the sample size (horizontal axis). In our experiments, we set the significance level (type-I error threshold) to be 10^{-4} .

understanding how, for a given significance level, the power of their test will change as the sample size increases. Our simulations confirm the intuition that — for the same number of samples — a higher sequencing depth always allows to achieve a better power, when H_0 is true.

The extent to which having a higher sequencing depth is important, however, depends on a number of factors. In particular, if the goal is to achieve a given level of power, we expect that different datasets will require different sequencing choices. For example, if the disease under study is characterized by a large excess ratio, relatively lower depth might suffice to achieve the desired power. Instead, if the excess ratio is close to one, higher depth might be needed to achieve the desired power. To highlight this, we show in Figure 7 results for three different couples of datasets of affected and unaffected subpopulations. Each couple of datasets was drawn from our model under different configurations of the hyperparameters. In each case, we enforce the null hypothesis H_0 to be true, by choosing the hyperparameters in such a way that the affected individuals show a larger number of singletons than the unaffected individuals. In general, and as expected, larger number of samples and higher sequencing depth always lead to improved power. However, the extent to which choosing a larger sequencing depth affects the power (hence, the usefulness) of the experiments, is greatly affected by the characteristics of the data: when (i) fewer variants are present and (ii) the excess variants ratio is small, a relatively higher depth is needed in order to achieve a given level of power.



Figure 8: Power analysis under fixed budget. For each subplot, we consider two different subpopulations (affected, and unaffected individuals respectively) — each group driven by different sets of hyperparameters (left: $\xi_A = [10, 4, 0.2], \xi_U = [7, 3, 0.1]$, center: $\xi_A = [15, 8, 0.5], \xi_U = [14, 6, 0.4]$, right: $\xi_A = [24, 12, 0.5], \xi_U = [20, 10, 0.3]$). In each subplot, we report the power of the singletons burden test (vertical axis) as we increase the sequencing depth (horizontal axis), under a fixed budget constraint, the assumption of balanced samples (same number of samples from each subpopulation) and given the cost function $c(m, \lambda) = 2m\lambda$. Different colored lines report the power for a different budget as a function of the implicit feasible sample sizes $M_A = M_U$, as we vary λ . In our experiment, we set the significance level to be 10^{-4} .

Fixed budget. We conclude this set of experiments with results for the other scenario of interest, the "fixed budget" case (Q2). Here, we consider instead the setting in which scientists have the ability to choose the sequencing depth, but are limited by a finite, fixed budget. As shown in Figure 8, a clear trade-off emerges. On the one hand, sequencing with a smaller depth allows scientists to collect larger cohorts of individuals, and potentially reveal large numbers of rare variants. However, if the sequencing depth is too low, many variants are missed due to noise in the sampling process. As a consequence, the associated power of the test is low. On the other hand, sequencing with a higher depth has the benefit that most variants, including rare ones, are detected in the sampling process. However, under a fixed budget, the cost of sequencing forces relatively smaller sample sizes. The best choice is then obtained by balancing between a sufficiently high sequencing depth, and large sampling cohort. Again, we point out that under different hyperparameters of the data generating process, different optimal choices of sequencing depth would emerge, even for the same budget. Our results are qualitatively in line with the findings of Rashkin et al. [2017, Figure 4 and 5].

D Improvements of the Bayesian framework

The model proposed in Appendix B enjoys a number of benefits: its theoretical properties are well understood, it is amenable to straightforward computation, and it has been previously largely and successfully employed in the applied literature (see, e.g. Griffiths and Ghahramani [2011] for a review). However, this model also suffers from a number of limitations for the task at hand:

- (a) Inability to jointly model a variant's occurrence in different subpopulations. In turn, this model is not useful for the hypothesis test H_0^* , which is designed to test for variants that are specific to one subpopulation.
- (b) Inability to model diploid sequences. Specifically, in Appendix B, we treat every observation as a *binary* vector of variants, in which we simply record the presence or absence of a discrepancy with respect to the reference genome. In reality, the human genome is diploid. That is, each variant can appear in either one, two or no copies. As such, it would be better model by values in {0, 1, 2}.

To overcome both these limitations, we now introduce an extension of the model proposed in Appendix B.3, building off the framework first proposed in Masoero et al. [2018].

D.1 A Bayesian nonparametric hierarchical model formulation

We start by addressing the first limitation — (a). This limitation is related to the choice of the prior distribution employed in Appendix B: that is, the way in which we model the distribution

of variants' frequencies. There, we proposed independent priors for the affected and unaffected subpopulations. In turn, this assumption does not allow us to reason about variants' frequencies jointly across multiple subpopulations. In particular, the model of Appendix B does not allow us to test us for the null hypothesis H_0^* .

To overcome this issue, we now formulate a richer hierarchical model. We assume that there exists a shared, latent distribution over the variants' frequencies. Again, just like we did in Appendix B, we assume that the distribution over these frequencies follows a Poisson point process, whose rate measure is given by Equation (9). We call the shared latent frequency of the k-th variant $\theta_{0,k}$. We collect the variants' frequencies, each with a corresponding label ψ_k , in a random measure:

$$\Theta_0 = \sum_k \theta_{0,k} \delta_{\psi_k} \sim 3BP(\alpha_0, c_0, \sigma_0).$$

Let now $J \ge 1$ be the number of subpopulations of interest. In what follows, we typically consider the case J = 2, for the two subpopulations of affected and unaffected individuals, as in our previous example. Then, for each subpopulation j = 1, ..., J, we assume that for every variant ψ_k in the shared prior measure Θ_0 , there exists a population-dependent probability of observing a variant at the k-th locus in the j-th subpopulation. We call this probability $\theta_{j,k}$, and assume that it is characterized by the distribution already given in Equation (4):

$$\theta_{j,k} \mid \Theta_0 \sim \text{Beta} \left\{ a_j \theta_{0,k}, b_j (1 - \theta_{0,k}) \right\}.$$

That is, for every variant, the probability of observing it in population j (i) can vary in different populations but (ii) depends on the underlying shared parameter $\theta_{0,k}$. For each population, we collect these probabilities, together with the labels ψ_k in another random measure, Θ_j :

$$\Theta_j \mid \Theta_0 = \sum_k \theta_{j,k} \delta_{\psi_k},$$

and we denote the distribution as the vector of random measures $\Theta_1, \ldots, \Theta_J$ as

$$[\Theta_1, \dots, \Theta_J] \mid \Theta_0 \sim h3BP(a_{1:J}, b_{1:J}; \Theta_0).$$
(16)

We refer to the vector of random measures $[\Theta_1, \ldots, \Theta_J]$, as a "hierarchical three-parameter Beta process" [h3BP].

D.2 Diploid observations: beyond Bernoulli processes

Next, we move on to address the second limitation — (b). This limitation is instead due to the choice of the likelihood model employed in Appendix B. Namely, the choice of a simple Bernoulli process for the observational data. While the assumption of binary observations in the context of genomic discovery has been widely used in the literature [Ionita-Laza et al., 2009, Ionita-Laza and Laird, 2010, Gravel, 2014, Zou et al., 2016, Chakraborty et al., 2019], in reality the human genome is diploid. I.e. it would better modeled by a variable that can take on three different values: either no variation at all ("aa", homozygous reference), variation at one of the two copies ("aA" or "Aa", heterozygous), or variation on both copies ("AA", homozygous variant). Then, for each site ℓ and each observation n in population j, the underlying genotype expression g would better be represented by a "ternary" variable, $g \in \{0, 1, 2\}$, where g = 0 when the site is non-variant homozygous ("aa"), g = 1 for a heterozygous site ("AA" or "Aa") and g = 2 for a variant homozygous site ("AA").

Following standard assumptions in the genomics literature [Wigginton et al., 2005, Mayo, 2008], we assume Hardy-Weinberg equilibrium [HWE] proportions. That is, conditionally on the variant's frequency (in population j) $\theta_{j,k}$, in the absence of sequencing errors,

$$\operatorname{pr}(X_{j,n,k} = g \mid \theta_{j,k}) = \begin{cases} (1 - \theta_{j,k})^2 & \text{if } g = 0\\ 2(1 - \theta_{j,k})\theta_{j,k} & \text{if } g = 1 \\ \theta_{j,k}^2 & \text{if } g = 2 \end{cases}$$
(17)

The *n*-th observation in the *j*-th subpopulation is then a generalization of the Bernoulli process — a multinomial process, denoted as

$$X_{j,n} \mid \Theta_j = \sum_{\ell \ge 1} X_{j,n,\ell} \delta_{\psi_\ell} \sim \text{MultiP}(\Theta_j, h(\cdot)).$$

Here $h : [0,1] \to [0,1]^3$ is the function which takes as input a variant's probability $\theta \in [0,1]$ and returns the corresponding Hardy-Weinberg proportions,

$$h(\theta) = \begin{bmatrix} (1-\theta)^2, & 2\theta(1-\theta), & \theta^2 \end{bmatrix}^+$$

and each variant appears according to the HWE proportions given in Equation (17), i.e.

$$X_{j,n,\ell} \mid \Theta_j \sim \text{Multinomial}\left((1-\theta_{j,\ell})^2, 2\theta_{j,\ell}(1-\theta_{j,\ell}), \theta_{j,\ell}^2\right).$$

D.3 Sequencing error in the hierarchical diploid model

Next, we have to discuss how the presence of noise in sequencing affects the results from our model. We here assume the same error model as the one introduced in Appendix B.2, with the only difference that now, whenever sufficiently many reads are produced, the correct haploid or diploid variant is called. I.e., again

Hence, it follows

$$Z_{j,n,\ell} = \mathbf{1}(C_{j,n,\ell,\text{noerror}} > D)X_{j,n,\ell}.$$
$$X_{n,j} \mid \Theta_j \sim \text{MultiP}(\phi\Theta_j, h(\cdot)),$$

i.e.

$$\operatorname{pr}(X_{n,j} = g \mid \Theta_j, \lambda, D) = \begin{cases} (1 - \phi \theta_{j,k})^2 & \text{if } g = 0\\ 2(1 - \phi \theta_{j,k})\phi \theta_{j,k} & \text{if } g = 1\\ (\phi \theta_{j,k})^2 & \text{if } g = 2 \end{cases}$$

with $\phi = \phi(\lambda, D, p_{err}, T) = 1 - \operatorname{pr}(Y > D)$, for $Y \sim \operatorname{Poisson}((1 - p_{err})\lambda)$. To sum up,

$$\Theta_{0} \sim 3BP(\alpha_{0}, c_{0}, \sigma_{0}),$$

$$[\Theta_{1}, \dots, \Theta_{J}] \mid \Theta_{0} \sim h3BP(a_{1:J}, b_{1:J}; \Theta_{0}),$$

$$X_{j,n} \mid \Theta_{j} \sim \text{MultiP}(\phi\Theta_{j}, h(\cdot)).$$
(18)

We discuss possible extension to alternative variant calling rules, e.g. based on genotype likelihoods, in Section 4.

D.4 Data generation and power trade-offs in the hierarchical model

We now have all the necessary ingredients to discuss how this hierarchical model can prove useful for power trade-off considerations. First, recall the non-hierarchical setting. The experiments for power maximization presented in Appendix C exploit the analytic predictive distribution for the number of new, yet unobserved (potentially, rare) variants, given in Proposition 2. In principle, we could do the same in the hierarchical setting: i.e. we could exploit the posterior characterization provided in Masoero et al. [2018, Theorem 2] and derive analogous analytic formulae for the posterior predictive distribution of the number of new, rare variants in the hierarchical setting. In practice, however, in the hierarchical setting such formulae do not enjoy the same practicality and simplicity of their univariate counterpart. In particular, the hierarchical model here adopted is such that the number of new, rare variants to be observed in either number of subpopulations is still Poisson distributed, but the parameter of such distribution is only available in an integral form, due to the lack of conjugacy in the hierarchical model. We find that computation of such integral is prone to numerical error.

Therefore, in our experiments, instead of relying on the analytic characterization of the number of new rare variants, we resort to simulation: specifically, we approximate the expected number of new rare variants by Monte Carlo approximation: because the hierarchical model in Equation (18) provides us with a full generative scheme, we can repeatedly draw from the model, and approximate the number of new rare variants by Monte Carlo averaging.

E Experiments from the hierarchical model

We now move on to the empirical evaluation of the properties of the Bayesian hierarchical model introduced in Appendix D. First, in Appendix E.1, we start by analyzing the effect of the additional parameters a_j, b_j , to understand how the hierarchical model differs from the three-parameter beta-Bernoulli used in Appendix C. In what follows, we adopt the same default specifications as in Appendix C for the threshold parameter D = 30 and the error $p_{error} = 0.05$.



Figure 9: Predictive behavior for the h3BP-Multinomial model under different choices of the generative parameters. Here, we focus on the case of two populations. The two left columns show the genotype matrices $X^{(j)} = [X_{j,n,k}] \in \{0, 1, 2\}^{N_j \times K}$, in which $X_{j,n,k} = 0$ (purple) if the *n*-th observation shows no variation at locus $k, X_{j,n,k} = 1$ (green) if there is a heterozygous variant, and $X_{j,n,k} = 2$ (yellow) if the variant is homozygous. The third and fourth columns show the total number of distinct homozygous and heterozygous variants present in the underlying genotype matrices $X_{j,n,k}$. We show in the third column the number of loci in which at least one heterozygous variant is detected (vertical axis) as a function of the sample size (horizontal axis), while in the fourth column we display the same quantity, now for heterozygous variants. Different colors are used to refer to different populations. Different line-styles are used to denote different sequencing depths. Different rows refer to different choices of the underlying hyperparameters $\boldsymbol{\xi}_0 = [\alpha_0, c_0, \sigma_0]$ — first row: $\boldsymbol{\xi}_0 = [20, 10, 0.1]$ (first row), $\boldsymbol{\xi}_0 = [25, 15, 0.2]$ (second row) and $\boldsymbol{\xi}_0 = [30, 20, 0.3]$ (third row). For all rows, we set $a_1 = 200, a_2 = 100$, and $b_1 = b_2 = 100$.

E.1 New, rare and excess variants in the Bayesian nonparametric hierarchical model

The hierarchical model introduced in Appendix D allows us to jointly model occurrence of variants in multiple subpopulations. From a modeling standpoint, this is desirable, as the same variant could share the same role, even in different subpopulations. In our discussion, we let subpopulation 1 be the "cases" (affected subpopulation), and subpopulation 2 be the controls (unaffected subpopulation). To understand the properties of the model, we start by analyzing the effect of the hyperparameters α_0, c_0, σ_0 on the data generating process. These parameters directly govern the underlying base measure Θ_0 . Similarly to what we discussed in Appendix C, also in the hierarchical setting these parameters control the rate of growth of the total number of variants, similarly as the univariate counterpart. Larger values of α_0 scale linearly the number of variants we expect to see, while larger values of c_0, σ_0 tend to favor a larger number of rare variants. To provide intuition, we show simple draws from the hierarchical model in Figure 9.

Next, we move on to the discussion of the hyperparameters a_j, b_j , for j = 1, ..., J. These parameters have an important role for determining the distribution of the variant's distribution in each subpopulation: for a given locus ℓ with underlying common base frequency $\theta_{0,\ell} \in [0, 1]$, from the representation in Equation (4), it follows that

$$\mathbb{E}[\theta_{j,k} \mid \theta_{0,k}] = \frac{a_j \theta_{0,k}}{b_j + (a_j - b_j) \theta_{0,k}},$$
(19)

and

$$\operatorname{Var}[\theta_{j,k} \mid \theta_{0,k}] = \frac{a_j b_j \theta_{0,k} (1 - \theta_{0,k})}{\left(b_j + (a_j - b_j)\theta_{0,k}\right)^2 \left(1 + \theta_{0,k} + (a_j - b_j)\theta_{0,k}\right)}.$$
(20)



Figure 10: Predictive behavior for the h3BP-Multinomial model under different choices of the generative specifications. Here, we fix hyperparameters for the underlying shared frequencies Θ_0 : $\alpha_0 = 10, c_0 = 4, \sigma_0 = 0.7$. We fix hyperparameters $b_1 = a_2 = b_2 = 100$, and consider three possible values for $a_1 \in \{150, 200, 250\}$. For each configuration of the hyperparameters, we report the predictive behavior by generating from the model.



Figure 11: Predictive behavior for the h3BP-Multinomial model under different choices of the generative parameters. Under the same model specifications as in Figure 10, we now focus on "exclusive" variants — namely variants that appear only in population j = 1, and do not appear in population j = 2.

That is to say, the parameters a_j , b_j control the dispersion of the hierarchical frequencies with respect to the underlying "base" frequencies. We show in Figures 10 and 11 how different choices of a_j can impact the rate of growth of distinct variants, as well as rare variants (singletons, doubletons). In Figure 10 we focus on variants that appear in the affected population, and also, potentially, in the unaffected subpopulation. Instead, we focus on those variants that appear *exclusively* in the affected subpopulation in Figure 11. Different choices of the hyperparameters have a great impact on the rate of growth of the number of variants; this shows that our model has the ability to capture a wide range of different data generating behaviors.

E.2 Power analysis with the hierarchical model

We now move to the power analysis for the hierarchical model. Again, we focus on the two questions -Q1 and Q2 - already investigated with the univariate model.

In Figure 1, we consider the "fixed-design" case (Q1), in which we analyze how the power of the singleton burden test — now for H_0^* (Equation (5)) — changes as we simultaneously increase the sizes of the control and the affected subpopulations, under a fixed sequencing depth. Larger sample sizes, and higher sequencing depths, are never harmful for power. However, the rate at which the power increases depends on the underlying hyperparameters of the process. When working with real data, therefore, different sequencing strategies could prove more or less effective in different contexts. In particular, if the experiment under study has the goal of achieving a desired level of power, our framework could allow practitioners to provide estimates of the budget needed in order to achieve the desired power level.

Next, we move on to the analysis of the second problem considered in our introduction — the power maximization under a fixed budget (Q2). We here consider both singletons, as in Appendix C, as well as k-tons — i.e. all variants appearing at most k times — for $k \in \{2, 3, 4, 5\}$. Under our



Figure 12: Under the same generative specifications as Figure 2, we report results for the k-tons burden test, for k = 2 (blue), k = 3 (orange), k = 4 (green), and k = 5 (red) under the same, fixed budget of B = 5000 units, where the cost $c(m, \lambda) = m\lambda$.

assumptions, we find that the optimal choice of the sequencing depth — i.e. the depth maximizing the corresponding test power under a fixed budget constraint:

- is relatively insensitive to the available budget: that is, under a given set of experimental hyperparameters for the data generating process, the optimal sequencing depth will tend to be similar for different available budgets. See e.g. Figure 2. These findings are in line with Rashkin et al. [2017, Figures 4,5].
- depends more heavily on the type of the test. We find that (i) tests for extremely rare variants generally achieve higher power than tests for relatively less rare variants, and that (ii) the optimal sequencing depth is typically lower for tests of extremely rare variants (see Figure 12).

The intuition behind this behavior has to be sought in the properties of the model's frequencies distribution: the underlying three-parameter beta process prior suggests that most variants will be extremely rare. Therefore, when testing for extremely rare variants, the test has sufficient power even when the sequencing depth is relatively lower, just because on average the affected population will reveal a larger number of singletons with respect to the unaffected population. On the contrary, when testing for relatively more frequent variants (e.g., k-tons), a larger depth is needed in order to capture a significant discrepancy between the affected, and unaffected population.